eravacycline (Xerava) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens. It was first approved by the FDA on August 27, 2018. Eravacycline disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.   NCATS

  • SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(F)C=C(NC(=O)CN5CCCC5)C(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
  • Mol. Mass: 558.5554
  • ALogP: 0.29
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$441.9700 - $579.1400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline | eravacycline | eravacycline dihydrochloride | eravacyline | tp-434


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue